OBJECTIVES: The Malawi antiretroviral therapy (ART) programme uses the public health approach to identify ART failure. Advanced disease progression may occur before switching to second-line ART. We report outcomes for patients evaluated and initiated on second-line treatment in Malawi. METHODS: Patients meeting Malawi immunological or clinical criteria for ART failure in two large urban ART clinics were evaluated for virological failure (viral load >400 HIV-1 RNA copies/mL) and, if failure was confirmed, initiated on second-line ART (zidovudine/lamivudine/tenofovir/lopinavir/ritonavir). Patients were seen monthly and laboratory evaluations were performed quarterly and as needed. We performed logistic regression modelling to identify factors associated with mortality, mortality or new HIV illnesses, and virological suppression at 12 months. RESULTS: Of the 109 patients with confirmed virological failure, five patients died prior to initiation, three declined switching and 101 patients initiated second-line treatment. Over 12 months, 10 additional patients died, 34 patients experienced 45 HIV-related events, and 19 patients experienced grade 3 or 4 toxicities. Among survivors, 85.2% had HIV-1 RNA<400 copies/mL at 12 months. While power to distinguish differences was limited, response rates were similar regardless of baseline resistance level. The median CD4 count increase was 142 cells/microL. World Health Organization clinical failure at baseline [odds ratio (OR) 3.47; 95% confidence interval (CI) 1.14-10.59] and body mass index <18.5 (OR 4.43; 95% CI 1.15-17.12) were risk factors for death. Baseline CD4 count <50 cells/microL was associated with increased risk for death or morbidity at 12 months (OR 2.57; 95% CI 1.01-6.52). CONCLUSIONS: Second-line treatment in Malawi was associated with substantial mortality, morbidity and toxicity but, among survivors, virological outcomes were favourable.
OBJECTIVES: The Malawi antiretroviral therapy (ART) programme uses the public health approach to identify ART failure. Advanced disease progression may occur before switching to second-line ART. We report outcomes for patients evaluated and initiated on second-line treatment in Malawi. METHODS:Patients meeting Malawi immunological or clinical criteria for ART failure in two large urban ART clinics were evaluated for virological failure (viral load >400 HIV-1 RNA copies/mL) and, if failure was confirmed, initiated on second-line ART (zidovudine/lamivudine/tenofovir/lopinavir/ritonavir). Patients were seen monthly and laboratory evaluations were performed quarterly and as needed. We performed logistic regression modelling to identify factors associated with mortality, mortality or new HIV illnesses, and virological suppression at 12 months. RESULTS: Of the 109 patients with confirmed virological failure, five patients died prior to initiation, three declined switching and 101 patients initiated second-line treatment. Over 12 months, 10 additional patients died, 34 patients experienced 45 HIV-related events, and 19 patients experienced grade 3 or 4 toxicities. Among survivors, 85.2% had HIV-1 RNA<400 copies/mL at 12 months. While power to distinguish differences was limited, response rates were similar regardless of baseline resistance level. The median CD4 count increase was 142 cells/microL. World Health Organization clinical failure at baseline [odds ratio (OR) 3.47; 95% confidence interval (CI) 1.14-10.59] and body mass index <18.5 (OR 4.43; 95% CI 1.15-17.12) were risk factors for death. Baseline CD4 count <50 cells/microL was associated with increased risk for death or morbidity at 12 months (OR 2.57; 95% CI 1.01-6.52). CONCLUSIONS: Second-line treatment in Malawi was associated with substantial mortality, morbidity and toxicity but, among survivors, virological outcomes were favourable.
Authors: Hanneke M J Nijland; Rafaëlla F A L'homme; Gerard A Rongen; Peter van Uden; Reinout van Crevel; Martin J Boeree; Rob E Aarnoutse; Peter P Koopmans; David M Burger Journal: AIDS Date: 2008-05-11 Impact factor: 4.177
Authors: José R Arribas; Federico Pulido; Rafael Delgado; Alicia Lorenzo; Pilar Miralles; Alberto Arranz; Juan J González-García; Concepción Cepeda; Rafael Hervás; José R Paño; Francisco Gaya; Antonio Carcas; María L Montes; José R Costa; José M Peña Journal: J Acquir Immune Defic Syndr Date: 2005-11-01 Impact factor: 3.731
Authors: Esteban Ribera; Carlos Azuaje; Rosa M Lopez; Pere Domingo; Adria Curran; Maria Feijoo; Leonor Pou; Paquita Sánchez; Maria Antonia Sambeat; Joan Colomer; Josep Lluis Lopez-Colomes; Manuel Crespo; Vicenç Falcó; Imma Ocaña; Albert Pahissa Journal: J Antimicrob Chemother Date: 2007-02-16 Impact factor: 5.790
Authors: Patrice Severe; Paul Leger; Macarthur Charles; Francine Noel; Gerry Bonhomme; Gyrlande Bois; Erik George; Stefan Kenel-Pierre; Peter F Wright; Roy Gulick; Warren D Johnson; Jean William Pape; Daniel W Fitzgerald Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Andrew N Phillips; Deenan Pillay; Alec H Miners; Diane E Bennett; Charles F Gilks; Jens D Lundgren Journal: Lancet Date: 2008-04-26 Impact factor: 79.321
Authors: Steven J Reynolds; Gertrude Nakigozi; Kevin Newell; Anthony Ndyanabo; Ronald Galiwongo; Iga Boaz; Thomas C Quinn; Ron Gray; Maria Wawer; David Serwadda Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banhegyi; Kiat Ruxrungtham; Dorece Norris; Eric Lefebvre; Marie-Pierre de Béthune; Frank Tomaka; Martine De Pauw; Tony Vangeneugden; Sabrina Spinosa-Guzman Journal: Lancet Date: 2007-07-07 Impact factor: 79.321
Authors: Mina C Hosseinipour; Joep J G van Oosterhout; Ralf Weigel; Sam Phiri; Debbie Kamwendo; Neil Parkin; Susan A Fiscus; Julie A E Nelson; Joseph J Eron; Johnstone Kumwenda Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: John A Bartlett; Heather J Ribaudo; Carole L Wallis; Evgenia Aga; David A Katzenstein; Wendy S Stevens; Michael R Norton; Karin L Klingman; Mina C Hosseinipour; John A Crump; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Beatrice A Kallungal; Nagalingeswaran Kumarasamy Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Carole L Wallis; Maria A Papathanasopolous; Matthew Fox; Francesca Conradie; Prudence Ive; Catherine Orrell; Jennifer Zeinecker; Ian Sanne; Robin Wood; James McIntyre; Wendy Stevens Journal: Antivir Ther Date: 2011-11-18
Authors: Thomas Gsponer; Maya Petersen; Matthias Egger; Sam Phiri; Marloes H Maathuis; Andrew Boulle; Patrick Musondad; Hannock Tweya; Karin Peter; Benjamin H Chi; Olivia Keiser Journal: AIDS Date: 2012-01-02 Impact factor: 4.177
Authors: Gilles Wandeler; Florian Gerber; Julia Rohr; Benjamin H Chi; Catherine Orrell; Cleophas Chimbetete; Hans Prozesky; Andrew Boulle; Christopher J Hoffmann; Thomas Gsponer; Matthew P Fox; Marcel Zwahlen; Matthias Egger Journal: Antivir Ther Date: 2013-12-03
Authors: Eric N Ouattara; Eric L Ross; Yazdan Yazdanpanah; Angela Y Wong; Marion Robine; Elena Losina; Raoul Moh; Rochelle P Walensky; Christine Danel; A David Paltiel; Serge P Eholié; Kenneth A Freedberg; Xavier Anglaret Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731